title: HIV-associated lymphomas and gamma-herpesviruses.
abstract: Among the most common HIV-associated lymphomas are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with immunoblastic-plasmacytoid differentiation (also involving the central nervous system). Lymphomas occurring specifically in HIV-positive patients include primary effusion lymphoma (PEL) and its solid variants, plasmablastic lymphoma of the oral cavity type and large B-cell lymphoma arising in Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease. These lymphomas together with BL and DLBCL with immunoblastic-plasmacytoid differentiation frequently carry EBV infection and display a phenotype related to plasma cells. EBV infection occurs at different rates in different lymphoma types, whereas KSHV is specifically associated with PEL, which usually occurs in the setting of profound immunosuppression. The current knowledge about HIV-associated lymphomas can be summarized in the following key points: (1) lymphomas specifically occurring in patients with HIV infection are closely linked to other viral diseases; (2) AIDS lymphomas fall in a spectrum of B-cell differentiation where those associated with EBV or KSHV commonly exhibit plasmablastic differentiation; and (3) prognosis for patients with lymphomas and concomitant HIV infection could be improved using better combined chemotherapy protocols incorporating anticancer treatments and antiretroviral drugs.
authors.affiliation: Department of Pathology, National Cancer Institute of Milan, Milan, Italy. antonino.carbone@istitutotumori.mi.it
authors.forename: Antonino
authors.initials: A
authors.lastname: Carbone
authors.forename: Ethel
authors.initials: E
authors.lastname: Cesarman
authors.forename: Michele
authors.initials: M
authors.lastname: Spina
authors.forename: Annunziata
authors.initials: A
authors.lastname: Gloghini
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Schulz
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D018142:Gammaherpesvirinae / Q000472:pathogenicity*; D015497:HIV-1 / Q000472:pathogenicity*; D006566:Herpesviridae Infections / Q000628:therapy / Q000821:virology*; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000628:therapy / Q000821:virology*; D014412:Tumor Virus Infections / Q000473:pathology / Q000628:therapy / Q000821:virology
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents